These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15681984)

  • 1. Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices.
    White N; Maxwell C; Michelson J; Bedell C
    Cancer Nurs; 2005; 28(1):62-9. PubMed ID: 15681984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting.
    Flores IQ; Ershler W
    Clin J Oncol Nurs; 2010 Feb; 14(1):81-6. PubMed ID: 20118030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.
    Dolan S; Crombez P; Munoz M
    Eur J Oncol Nurs; 2005; 9 Suppl 1():S14-23. PubMed ID: 16207534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L; Untch M; Skacel T; Pico JL
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
    Renwick W; Pettengell R; Green M
    BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing hematologic toxicities: novel therapies.
    Nirenberg A
    Cancer Nurs; 2003 Dec; 26(6 Suppl):32S-37S. PubMed ID: 15025411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
    Ozer H
    Curr Opin Hematol; 1996 Jan; 3(1):3-10. PubMed ID: 9372045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid growth factors clinical practice guidelines in oncology.
    Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
    J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
    [No Abstract]   [Full Text] [Related]  

  • 15. New treatment options for managing chemotherapy-induced neutropenia.
    Valley AW
    Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S11-7. PubMed ID: 12166032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors for chemotherapy-induced neutropenia.
    Yalçin S
    Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202
    [No Abstract]   [Full Text] [Related]  

  • 17. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
    Petros WP
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):1S-2S; quiz 20S-23S. PubMed ID: 12921215
    [No Abstract]   [Full Text] [Related]  

  • 18. Filgrastim in patients with neutropenia: potential effects on quality of life.
    Lyman GH; Kuderer NM
    Drugs; 2002; 62 Suppl 1():65-78. PubMed ID: 12479595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].
    Murakawa Y
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.
    Stull DM; Bilmes R; Kim H; Fichtl R
    Am J Health Syst Pharm; 2005 Jan; 62(1):83-7. PubMed ID: 15658078
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.